Literature DB >> 20627700

Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency.

T Freiberger1, L Grodecká, B Ravcuková, B Kurecová, V Postránecká, J Vlcek, J Jarkovský, V Thon, J Litzman.   

Abstract

The neonatal Fc receptor (FcRn) acts as a key regulator of IgG homeostasis and is an important sensor of luminal infection. We analyzed the influence of FcRn expression on disease phenotype and the catabolism of therapeutically administered intravenous immunoglobulins (IVIG) in 28 patients with common variable immunodeficiency (CVID). Patients with generalized bronchiectasis and fibrosis had lower levels of FCRN mRNA compared to patients without these complications (P=0.027 and P=0.041, respectively). Moreover, FCRN mRNA levels correlated negatively with the extent of bronchiectasis and the rate of IgG decline after infusion of IVIG (P=0.027 and P=0.045, respectively). No relationship of FCRN expression with age at disease onset, age at diagnosis, diagnostic delay, IgG levels or frequency of infections before or during replacement immunoglobulin treatment, the presence of lung functional abnormalities, chronic diarrhea, granulomas, lymphadenopathy, splenomegaly or autoimmune phenomena was observed. Our results showed that FcRn might play a role in the development of lung structural abnormalities and in the catabolism of IVIG in patients with CVID. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627700     DOI: 10.1016/j.clim.2010.05.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  14 in total

Review 1.  Considerations for dosing immunoglobulin in obese patients.

Authors:  J P Hodkinson
Journal:  Clin Exp Immunol       Date:  2017-04-17       Impact factor: 4.330

2.  Influence of FCRN expression on lung decline and intravenous immunoglobulin catabolism in common variable immunodeficiency patients.

Authors:  J Litzman
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

3.  Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor.

Authors:  E Oksenhendler
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181.

Authors:  Daniel C Ferguson; Javier G Blanco
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

5.  Functional polymorphisms in rhesus macaque FCGRT and β2-m.

Authors:  Zhanna Shubin; Yutaka Tagaya; Bhawna Poonia
Journal:  Immunogenetics       Date:  2017-08-07       Impact factor: 2.846

Review 6.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

Authors:  S Jolles; J S Orange; A Gardulf; M R Stein; R Shapiro; M Borte; M Berger
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

7.  Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor.

Authors:  V Gouilleux-Gruart; H Chapel; S Chevret; M Lucas; M Malphettes; C Fieschi; S Patel; D Boutboul; M-N Marson; L Gérard; M Lee; H Watier; E Oksenhendler
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

8.  Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.

Authors:  Christophe Passot; Nicolas Azzopardi; Sylvaine Renault; Nadine Baroukh; Christophe Arnoult; Marc Ohresser; Michèle Boisdron-Celle; Erick Gamelin; Hervé Watier; Gilles Paintaud; Valérie Gouilleux-Gruart
Journal:  MAbs       Date:  2013-04-25       Impact factor: 5.857

9.  Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients.

Authors:  J P Hodkinson; M Lucas; M Lee; M Harrison; M P Lunn; H Chapel
Journal:  Clin Exp Immunol       Date:  2015-05-25       Impact factor: 4.330

10.  Proteomic analysis of sera from common variable immunodeficiency patients undergoing replacement intravenous immunoglobulin therapy.

Authors:  Giuseppe Spadaro; Concetta D'Orio; Arturo Genovese; Antonella Galeotafiore; Chiara D'Ambrosio; Stefano Di Giovanni; Monica Vitale; Mario Capasso; Vincenzo Lamberti; Andrea Scaloni; Gianni Marone; Nicola Zambrano
Journal:  J Biomed Biotechnol       Date:  2011-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.